Even now 65 percent of drugs being approved come from biopharma companies and within a decade that is expected to rise to 85 percent. This is great news for a world hungry for new breakthrough treatments. As growth in pre-clinical and clinical work intensifies globally, Ahmed Bouzidi, Vice President of Biotech Strategic Development at ProductLife Group, explores the place of biopharma start-ups in the wider life sciences ecosystem – and the potential for new partnerships to accelerate their speed to market.
The biopharmaceutical industry, and innovative small and medium businesses in particular, has been centre stage in tackling COVID-19. Small or modest-size biopharma companies inherently possess several market advantages; they are flexible, adaptable and geared to taking novel approaches to medical challenges. Today biopharmaceutical medicines are also experiencing greater acceptance than they ever have previously by global populations. That is, confidence in more experimental or non-traditional products has soared during the pandemic, paving the way for biopharma small or medium-sized enterprises (SMEs) to become major players in the global market.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
In 2017, about 65 percent of the drugs approved in the market were based on biotechnology, according to United Nations (UN) statistics, and this trend is expected to accelerate in the coming years. The huge demand for biopharmaceutical will be facilitated by an accelerating focus on research and related investment, fanned by the COVID-19 pandemic. Additionally, the ability of biopharmaceutical products to address previously untreatable conditions will fuel the introduction of innovative drugs to the market, bolstering the biopharmaceutical market over the next decade.
Filling gaps in today’s treatments
Biopharma companies are actively involved in the development of innovative molecules that fulfil the unmet needs of patients. With an increasing number of companies in the late-stage development of their biologics, it is anticipated that the biologics market will witness substantial growth in the future. The soaring number of product approvals and increasing demand for targeted therapies, as well as the rise in the development of biosimilars, will contribute to this growth.
But the right conditions need to be aligned to realise the potential and currently some regional markets are more favourable than others for the ambitious biopharma company.
Tomorrow, the market will be in part driven by the emergence of new diseases triggering the need for effective vaccines and novel therapies. This, in turn, will drive increasing demand for faster approval processes, a transformed regulatory landscape and growth in emerging fields – such as specialty therapies, vaccines, orphan drug, or personalised medicines for indications in the fields of cancer, chronic diseases and emerging infectious diseases. All of this will attract increasing attention from investors and big pharma.
Despite the rising interest in biopharma and all that regulators have done to ease these products’ path to market, the funding and pro-active support available for bringing drugs to market varies internationally. The biggest barrier for EU biopharma companies remains raising the capital necessary to bring products from early research to commercialisation. Certainly, investment in European biopharma companies is increasing, but late-stage financing in Europe lags well behind the US, where biopharma companies receive almost five times as much private funding as their European counterparts.
Global funding/support disparity points to the partnership option
The EU in particular has some work to do to create more conducive conditions in which biopharma innovators can thrive independently – certainly compared to the US and Asian markets. The gap is especially marked for biotech companies raising larger amounts in late-stage private-venture-financing rounds or on public markets. For example, biotech initial public offerings (IPOs) are three times larger on Nasdaq than on European exchanges, so European biotech firms tend to look to the US for growth capital.
The biggest barrier for EU biopharma companies remains raising the capital necessary to bring products from early research to commercialisation”
The German biotech company BioNTech is a case in point; not only did it collaborate with a US company, Pfizer, to develop its breakthrough messenger RNA (mRNA) COVID-19 vaccine, but it also chose to trade on the Nasdaq, in addition to the Frankfurt Stock Exchange, to raise more funds. Since 2012, almost a third of European biotech companies filing for an IPO have done so directly on US exchanges.
Moderna in the US was able to take its own mRNA COVID-19 vaccine to market, thanks to the backing of substantial, risk-tolerant public financing.
In China, optimum conditions and the ready available of generous funding in both Hong Kong and on the mainland, has led to three vaccines being produced in the last 10 months, comparable with the US’s record.
The most notable innovation to come out of Europe during the pandemic has been the AstraZeneca/Oxford vaccine but, originating in the UK, even this success has happened outside the EU (following Brexit).
At a research level, Europe is a global powerhouse with world-class research institutions, medical centres and hospitals that provide a strong basis for sourcing and developing scientific and clinical innovations. Unfortunately, this early innovation is not translating into patents for new medicines. Indeed, the EU has not only fallen well behind the US, but also well behind innovators in the Asia Pacific, in particular China and Japan.
In 2017 and 2018, European companies were responsible for originating 13 percent of biotechnology drugs approved by US Food and Drug Administration (FDA) while US biotech companies were responsible for 78 percent.
If Europe wants to command a share of the biopharma revolution, the EU needs to address the current conservatism, sluggish timelines and regulatory complexity.
In an ideal world, biopharma SMEs would be able to bring their own products to market, with the right support, retaining the benefits of those companies’ agility and maximising market competition, drug affordability and global access to a choice of treatments.
However, the pandemic has also shown what is possible when companies and scientists work together to pool their expertise. In the coming years, if innovation is to continue at the scale seen during COVID-19; if production is to be made more efficient and cost-effective; and if weaknesses in supply chains are to be overcome, the only way forward will be to extend and expand partnerships between organisations and countries.
Certainly, pharmacovigilance will play an essential role in ensuring the safety of patients, especially as pharma branches out into more innovative treatments, and biopharma SMEs will need help with this.
Predicting the future
Looking ahead, the role of the biopharma sector looks set to play an increasingly prominent role, pointing to opportunities both for bold start-ups and for larger and more established names ready to give them a leg up. Alongside COVID-19, major drivers fuelling the growth of the biopharmaceutical market include an increase in the elderly population; the surge in prevalence of chronic diseases such as cancer and diabetes; and an increase in obesity and sedentary lifestyles among many populations – added to the growing acceptance of biopharmaceuticals due to their ability to successfully address previously untreatable diseases.
Approval for newer and more affordable biopharmaceutical products – not just branded but also biosimilar products (due to patent expiry of major pharmaceutical products) – will give rise to lucrative opportunities for market players, especially linked to low-cost alternatives to prohibitively expensive treatments for novel immuno-oncology products and the like.
Asian players will also play an increasingly important role in addressing and overcoming drug shortages”
New players, particularly from Asia, will play a pivotal role in providing such medicines at a more affordable cost. Although US players conduct over half the world’s pharma R&D today and hold the intellectual property rights on most new medicines, according to the Pharmaceutical Research and Manufacturers Association (PhRMA), the Asia-Pacific region’s market share is expected to grow at a steady pace of CAGR 8.34 percent between 2020-2027, due to optimum conditions to support innovation as well as price reforms.
Asian players will also play an increasingly important role in addressing and overcoming drug shortages. In recent years, the prevalence of medicine shortages reported in most EU countries has increased exponentially. In France, medicine shortages numbered 1,450 in 2019, almost double those of the previous year and a staggering uplift from the 44 recorded a decade earlier. A recent survey of the European Association of Hospitals Pharmacists (EAHP) pointed to the rising shortages of oncology medicines, with 47 percent of respondents stating that oncology products are among the medicines most commonly in shortage (up from 39 percent in 2018).
For biopharma innovators with so much opportunity ahead of them, there is a lot to think about. Considerations must include strategies for product development and the need to fulfil regulatory obligations at all stages of development as well as pre- and post-market. To maximise their potential, these companies must ensure they are targeting the right markets with the right medicines, that they have access to the scale of funding they need at the right stages and that they are able to safely fast-track delivery of much-needed treatments at an affordable and sustainable price point, harnessing the right partnerships as they go.
Ahmed Bouzidi is Vice President of Biotech Strategic Development at ProductLife Group (PLG). He has been at the forefront of the biopharma industry for more than 30 years, in three continents. He is a Senior Associate of the Royal Society of Medicines and previously has been President of the European Biopharmaceutical Enterprises (EBE) and a board member of Vaccines Europe (VE).
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.